{"id":"NCT04051463","sponsor":"Price Vision Group","briefTitle":"Rhopressa for Corneal Edema Associated With Fuchs Dystrophy","officialTitle":"Prospective Randomized Study to Determine Whether Use of Rhopressaâ„¢ Can Ameliorate Corneal Edema Associated With Fuchs Dystrophy","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2019-08-05","primaryCompletion":"2020-07-01","completion":"2020-07-01","firstPosted":"2019-08-09","resultsPosted":"2021-09-24","lastUpdate":"2021-10-19"},"enrollment":29,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Fuchs Endothelial Dystrophy"],"interventions":[{"type":"DRUG","name":"Netarsudil Ophthalmic Solution","otherNames":["Rhopressa"]},{"type":"DRUG","name":"Placebo","otherNames":["Rhopressa vehicle without active ingredient"]}],"arms":[{"label":"Netarsudil","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The study objective is to determine whether use of Rhopressa improves the ability of corneal endothelial cells to maintain appropriate corneal hydration in patients with Fuchs endothelial corneal dystrophy (FECD), which could help delay or prevent the need for a corneal transplant.","primaryOutcome":{"measure":"Change in Central Corneal Thickness","timeFrame":"1 month","effectByArm":[{"arm":"Netarsudil","deltaMin":-23,"sd":null},{"arm":"Placebo","deltaMin":-2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":8},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["33737034"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":15},"commonTop":["conjunctival hyperemia","ocular irritation","glare","lacrimation"]}}